We defined three molecular tumor subtypes based on HER2 and hormone receptor (HR) status: HER2+, HR+ (ER+ or PR+)/HER2-, and HER2-/ER-/PR- (triple negative, TNBC). This evidence concerns the gene NR4A1 and neoplasm.